The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease

Jen M. Ng, Michelle Cooke, Sunil Bhandari, Stephen Atkin, Eric S. Kilpatrick

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

OBJECTIVE - To examine the effect of intravenous iron and erythropoietin-stimulating agents (ESAs) on glycemic control and A1C of patients with diabetes and chronic kidney disease (CKD). RESEARCH DESIGN AND METHODS- This was a prospective study of patients with type 2 diabetes and CKD stage IIIB or IV undergoing intravenous iron (group A) and/or ESA (group B). Full blood profiles were determined over the study period. Glycemic control was monitored using A1C, seven-point daily glucose three times weekly, and continuous glucose monitoring (CGM). RESULTS - There were 15 patients in both group A and group B. Mean A1C (95% CI) values fell in both groups (7.40% [6.60-8.19] to 6.96% [6.27-7.25], P < 0.01, with intravenous iron and 7.31% [6.42-8.54] to 6.63% [6.03-7.36], P = 0.013, ESA). There was no change in mean blood glucose in group A (9.55 mmol/l [8.20-10.90] vs. 9.71 mmol/l [8.29-11.13], P = 0.07) and in group B (8.72 mmol/l [7.31-10.12] vs. 8.78 mmol/l [7.47-9.99], P=0.61) over the study period. Hemoglobin and hematocrit values significantly increased following both treatments. There was no linear relationship found between the change in A1C values and the rise of hemoglobin following either treatment. CONCLUSIONS - Both iron and ESA cause a significant fall in A1C values without a change to glycemic control in patients with diabetes and CKD. At the present time, regular capillary glucose measurements and the concurrent use of CGM remain the best alternative measurements of glycemic control in this patient group.

Original languageEnglish
Pages (from-to)2310-2313
Number of pages4
JournalDiabetes Care
Volume33
Issue number11
DOIs
Publication statusPublished - Nov 2010
Externally publishedYes

Fingerprint

Erythropoietin
Chronic Renal Insufficiency
Iron
Glucose
Hemoglobins
Therapeutics
Hematocrit
Type 2 Diabetes Mellitus
Blood Glucose
Research Design
Prospective Studies

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialised Nursing

Cite this

The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease. / Ng, Jen M.; Cooke, Michelle; Bhandari, Sunil; Atkin, Stephen; Kilpatrick, Eric S.

In: Diabetes Care, Vol. 33, No. 11, 11.2010, p. 2310-2313.

Research output: Contribution to journalArticle

Ng, Jen M. ; Cooke, Michelle ; Bhandari, Sunil ; Atkin, Stephen ; Kilpatrick, Eric S. / The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease. In: Diabetes Care. 2010 ; Vol. 33, No. 11. pp. 2310-2313.
@article{4bfdde438fb0480b9e5b9121988e1efd,
title = "The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease",
abstract = "OBJECTIVE - To examine the effect of intravenous iron and erythropoietin-stimulating agents (ESAs) on glycemic control and A1C of patients with diabetes and chronic kidney disease (CKD). RESEARCH DESIGN AND METHODS- This was a prospective study of patients with type 2 diabetes and CKD stage IIIB or IV undergoing intravenous iron (group A) and/or ESA (group B). Full blood profiles were determined over the study period. Glycemic control was monitored using A1C, seven-point daily glucose three times weekly, and continuous glucose monitoring (CGM). RESULTS - There were 15 patients in both group A and group B. Mean A1C (95{\%} CI) values fell in both groups (7.40{\%} [6.60-8.19] to 6.96{\%} [6.27-7.25], P < 0.01, with intravenous iron and 7.31{\%} [6.42-8.54] to 6.63{\%} [6.03-7.36], P = 0.013, ESA). There was no change in mean blood glucose in group A (9.55 mmol/l [8.20-10.90] vs. 9.71 mmol/l [8.29-11.13], P = 0.07) and in group B (8.72 mmol/l [7.31-10.12] vs. 8.78 mmol/l [7.47-9.99], P=0.61) over the study period. Hemoglobin and hematocrit values significantly increased following both treatments. There was no linear relationship found between the change in A1C values and the rise of hemoglobin following either treatment. CONCLUSIONS - Both iron and ESA cause a significant fall in A1C values without a change to glycemic control in patients with diabetes and CKD. At the present time, regular capillary glucose measurements and the concurrent use of CGM remain the best alternative measurements of glycemic control in this patient group.",
author = "Ng, {Jen M.} and Michelle Cooke and Sunil Bhandari and Stephen Atkin and Kilpatrick, {Eric S.}",
year = "2010",
month = "11",
doi = "10.2337/dc10-0917",
language = "English",
volume = "33",
pages = "2310--2313",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "11",

}

TY - JOUR

T1 - The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease

AU - Ng, Jen M.

AU - Cooke, Michelle

AU - Bhandari, Sunil

AU - Atkin, Stephen

AU - Kilpatrick, Eric S.

PY - 2010/11

Y1 - 2010/11

N2 - OBJECTIVE - To examine the effect of intravenous iron and erythropoietin-stimulating agents (ESAs) on glycemic control and A1C of patients with diabetes and chronic kidney disease (CKD). RESEARCH DESIGN AND METHODS- This was a prospective study of patients with type 2 diabetes and CKD stage IIIB or IV undergoing intravenous iron (group A) and/or ESA (group B). Full blood profiles were determined over the study period. Glycemic control was monitored using A1C, seven-point daily glucose three times weekly, and continuous glucose monitoring (CGM). RESULTS - There were 15 patients in both group A and group B. Mean A1C (95% CI) values fell in both groups (7.40% [6.60-8.19] to 6.96% [6.27-7.25], P < 0.01, with intravenous iron and 7.31% [6.42-8.54] to 6.63% [6.03-7.36], P = 0.013, ESA). There was no change in mean blood glucose in group A (9.55 mmol/l [8.20-10.90] vs. 9.71 mmol/l [8.29-11.13], P = 0.07) and in group B (8.72 mmol/l [7.31-10.12] vs. 8.78 mmol/l [7.47-9.99], P=0.61) over the study period. Hemoglobin and hematocrit values significantly increased following both treatments. There was no linear relationship found between the change in A1C values and the rise of hemoglobin following either treatment. CONCLUSIONS - Both iron and ESA cause a significant fall in A1C values without a change to glycemic control in patients with diabetes and CKD. At the present time, regular capillary glucose measurements and the concurrent use of CGM remain the best alternative measurements of glycemic control in this patient group.

AB - OBJECTIVE - To examine the effect of intravenous iron and erythropoietin-stimulating agents (ESAs) on glycemic control and A1C of patients with diabetes and chronic kidney disease (CKD). RESEARCH DESIGN AND METHODS- This was a prospective study of patients with type 2 diabetes and CKD stage IIIB or IV undergoing intravenous iron (group A) and/or ESA (group B). Full blood profiles were determined over the study period. Glycemic control was monitored using A1C, seven-point daily glucose three times weekly, and continuous glucose monitoring (CGM). RESULTS - There were 15 patients in both group A and group B. Mean A1C (95% CI) values fell in both groups (7.40% [6.60-8.19] to 6.96% [6.27-7.25], P < 0.01, with intravenous iron and 7.31% [6.42-8.54] to 6.63% [6.03-7.36], P = 0.013, ESA). There was no change in mean blood glucose in group A (9.55 mmol/l [8.20-10.90] vs. 9.71 mmol/l [8.29-11.13], P = 0.07) and in group B (8.72 mmol/l [7.31-10.12] vs. 8.78 mmol/l [7.47-9.99], P=0.61) over the study period. Hemoglobin and hematocrit values significantly increased following both treatments. There was no linear relationship found between the change in A1C values and the rise of hemoglobin following either treatment. CONCLUSIONS - Both iron and ESA cause a significant fall in A1C values without a change to glycemic control in patients with diabetes and CKD. At the present time, regular capillary glucose measurements and the concurrent use of CGM remain the best alternative measurements of glycemic control in this patient group.

UR - http://www.scopus.com/inward/record.url?scp=79951709585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951709585&partnerID=8YFLogxK

U2 - 10.2337/dc10-0917

DO - 10.2337/dc10-0917

M3 - Article

C2 - 20798337

AN - SCOPUS:79951709585

VL - 33

SP - 2310

EP - 2313

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 11

ER -